Seres Therapeutics has been granted a patent for a composition containing specific bacterial species encapsulated in a capsule, aimed at preventing and treating dysbiosis in mammals. The composition includes Clostridium orbiscindens, Clostridium bolteae, and Lachnospiraceae bacterium 5_1_57FAA to inhibit pathogenic bacteria growth. GlobalData’s report on Seres Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Seres Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Seres Therapeutics, Microbiota restoration therapy was a key innovation area identified from patents. Seres Therapeutics's grant share as of February 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.

Composition of isolated bacteria in capsule for dysbiosis treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Seres Therapeutics Inc

A recently granted patent (Publication Number: US11918612B2) discloses a composition comprising three different species of isolated bacteria capable of forming spores - Clostridium orbiscindens, Clostridium bolteae, and Lachnospiraceae bacterium 5_1_57FAA. These bacteria are encapsulated within a capsule, with the combination of the three species demonstrating the ability to decrease and/or inhibit the growth and colonization of various pathogenic bacteria. The composition is designed to target a wide range of pathogenic bacteria, including Yersinia, Vibrio, Streptococcus, Salmonella, Escherichia, and many others, making it a potentially versatile solution for combating harmful bacterial infections.

Moreover, the patent also includes claims related to the specific genetic sequences of the bacteria involved in the composition, highlighting the importance of genetic identity in their effectiveness. The composition can be administered as a single dose unit and may contain additional components such as glycerol. The synergistic effect of the three bacterial species in inhibiting pathogenic bacteria colonization is a key feature of this composition. Additionally, the patent mentions the enteric coating of the capsule, emphasizing the targeted delivery of the bacteria to specific areas within the body. Overall, this patented composition represents a novel approach to combating pathogenic bacterial infections through a combination of unique bacterial species encapsulated within a protective capsule.

To know more about GlobalData’s detailed insights on Seres Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies